title: [Perforation of the nasal septum: a rare complication of bevacizumab].
abstract: BACKGROUND
  Neovascularisation is a hallmark of cancer. Vascular endothelial growth factor (VEGF) is directly involved in the regulation of this tumoural neoangiogenesis, especially in lung cancer. Bevacizumab is a humanized monoclonal antibody targeting VEGF that is commonly used in thoracic oncology. Among the side effects, perforation of the nasal septum is rare.
  
  
  METHODS
  We report the case of a 50-year-old woman with adenocarcinoma of the right upper lobe, immediately metastatic, treated with five cycles of chemotherapy (cisplatin, gemcitabine, bevacizumab). She developed a perforation of the nasal septum after the third injection of bevacizumab given as monotherapy during the maintenance phase.
  
  
  CONCLUSIONS
  This is, to our knowledge, the first description of this complication in the course of treatment of bronchial carcinoma. Its management is purely symptomatic. The action to be taken in using bevacizumab is not fully codified.
authors.affiliation: Service de pneumologie, hôpital d'instruction des armées Desgenettes, 106 boulevard Pinel, Lyon, France. bylicki.olivier@yahoo.fr
authors.forename: O
authors.initials: O
authors.lastname: Bylicki
authors.forename: C
authors.initials: C
authors.lastname: Boursier
authors.forename: J-M
authors.initials: JM
authors.lastname: Peloni
authors.forename: J-M
authors.initials: JM
authors.lastname: Dot
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D005260:Female; D005971:Glutamates / Q000627:therapeutic use; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D060046:Maintenance Chemotherapy; D008875:Middle Aged; D061270:Nasal Septal Perforation / Q000139:chemically induced*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D000068437:Pemetrexed; D011799:Quinazolines / Q000627:therapeutic use; D012131:Respiratory Insufficiency / Q000209:etiology; D016879:Salvage Therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000093542:Gemcitabine
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005971:Glutamates; D009363:Neoplasm Proteins; D011799:Quinazolines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068437:Pemetrexed; D003841:Deoxycytidine; D000068258:Bevacizumab; D006147:Guanine; D000069347:Erlotinib Hydrochloride; D002945:Cisplatin; D000093542:Gemcitabine